AMO Pharma Plans Registrational Study for Congenital Myotonic Dystrophy Type 1
AMO Pharma announced plans for a registrational study evaluating its drug AMO-02 for congenital myotonic dystrophy type 1. The study will use hospitalization as the primary outcome measure, based on feedback from regulatory agencies including the FDA.
AMO Pharma is proceeding with a registrational clinical study for its investigational therapy AMO-02, aimed at treating congenital myotonic dystrophy type 1 (CDM1). The company announced on July 6, 2026, that the study design incorporates feedback received from scientific advice meetings with the U.S. Food and Drug Administration (FDA), the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.
The planned registrational study will evaluate hospitalization as the primary outcome measure. Multiple functional assessments will serve as secondary outcome measures. This revised approach follows guidance from the regulatory bodies to ensure the study design adequately addresses the disease’s impact.
Congenital myotonic dystrophy type 1 is a rare, inherited neuromuscular disorder characterized by prolonged muscle contraction, leading to progressive muscle weakness and other complications. Currently, treatment options are limited, focusing primarily on symptom management.
AMO Pharma has been developing AMO-02, a therapy designed to target the underlying mechanisms of CDM1. The company’s previous clinical trial data has informed the design of this upcoming pivotal study, aiming to demonstrate the drug's efficacy and safety for regulatory submissions.